173 related articles for article (PubMed ID: 27683179)
1. A Potent
Zhang KJ; Yin XF; Yang YQ; Li HL; Xu YN; Chen LY; Liu XJ; Yuan SJ; Fang XL; Xiao J; Wu S; Xu HN; Chu L; Katlinski KV; Katlinskaya YV; Guo RB; Wei GW; Wang DC; Liu XY; Fuchs SY
Clin Cancer Res; 2017 Apr; 23(8):2038-2049. PubMed ID: 27683179
[No Abstract] [Full Text] [Related]
2. Serum immunoglobulin fused interferon-alpha inhibited tumor growth in athymic mice bearing colon 26 adenocarcinoma cells.
Kim JS; Yu KN; Noh MS; Woo MA; Park SJ; Park JH; Hua J; Cho HS; Hwang SK; Lee ES; Chung YS; Choi IY; Kwon SC; Cho MH
J Vet Sci; 2008 Mar; 9(1):45-50. PubMed ID: 18296888
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative properties of chemically modified recombinant IFN-alpha2b.
Martynov AV; Smelyanskaya MV
J Interferon Cytokine Res; 2005 Jul; 25(7):414-7. PubMed ID: 16022586
[TBL] [Abstract][Full Text] [Related]
4. Emodin potentiates the antiproliferative effect of interferon α/β by activation of JAK/STAT pathway signaling through inhibition of the 26S proteasome.
He Y; Huang J; Wang P; Shen X; Li S; Yang L; Liu W; Suksamrarn A; Zhang G; Wang F
Oncotarget; 2016 Jan; 7(4):4664-79. PubMed ID: 26683360
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
Xuan C; Steward KK; Timmerman JM; Morrison SL
Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
[TBL] [Abstract][Full Text] [Related]
6. Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
Carbone CJ; Zheng H; Bhattacharya S; Lewis JR; Reiter AM; Henthorn P; Zhang ZY; Baker DP; Ukkiramapandian R; Bence KK; Fuchs SY
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19226-31. PubMed ID: 23129613
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C.
Mizukoshi E; Kaneko S; Kaji K; Terasaki S; Matsushita E; Muraguchi M; Ohmoto Y; Kobayashi K
Hepatology; 1999 Nov; 30(5):1325-31. PubMed ID: 10534358
[TBL] [Abstract][Full Text] [Related]
8. Differential receptor subunit affinities of type I interferons govern differential signal activation.
Jaks E; Gavutis M; Uzé G; Martal J; Piehler J
J Mol Biol; 2007 Feb; 366(2):525-39. PubMed ID: 17174979
[TBL] [Abstract][Full Text] [Related]
9. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
Bailon P; Palleroni A; Schaffer CA; Spence CL; Fung WJ; Porter JE; Ehrlich GK; Pan W; Xu ZX; Modi MW; Farid A; Berthold W; Graves M
Bioconjug Chem; 2001; 12(2):195-202. PubMed ID: 11312680
[TBL] [Abstract][Full Text] [Related]
10. Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity.
Fukushima M; Okabe H; Takechi T; Ichikawa W; Hirayama R
Cancer Lett; 2002 Dec; 187(1-2):103-10. PubMed ID: 12359357
[TBL] [Abstract][Full Text] [Related]
11. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.
Grace MJ; Lee S; Bradshaw S; Chapman J; Spond J; Cox S; Delorenzo M; Brassard D; Wylie D; Cannon-Carlson S; Cullen C; Indelicato S; Voloch M; Bordens R
J Biol Chem; 2005 Feb; 280(8):6327-36. PubMed ID: 15596441
[TBL] [Abstract][Full Text] [Related]
12. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
Sabbatino F; Wang Y; Scognamiglio G; Favoino E; Feldman SA; Villani V; Flaherty KT; Nota S; Giannarelli D; Simeone E; Anniciello AM; Palmieri G; Pepe S; Botti G; Ascierto PA; Ferrone CR; Ferrone S
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851802
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice.
Cao B; Chen XP; Zhu P; Ding L; Guan J; Shi ZL
World J Gastroenterol; 2008 Nov; 14(44):6802-7. PubMed ID: 19058305
[TBL] [Abstract][Full Text] [Related]
14. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.
Kalie E; Jaitin DA; Abramovich R; Schreiber G
J Biol Chem; 2007 Apr; 282(15):11602-11. PubMed ID: 17310065
[TBL] [Abstract][Full Text] [Related]
15. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Chang CH
Blood; 2009 Oct; 114(18):3864-71. PubMed ID: 19710501
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of cytokine-mediated receptor assembly using engineered FC heterodimers.
Deshpande A; Putcha BD; Kuruganti S; Walter MR
Protein Sci; 2013 Aug; 22(8):1100-8. PubMed ID: 23703950
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
Surgery; 2006 Aug; 140(2):297-306. PubMed ID: 16904983
[TBL] [Abstract][Full Text] [Related]
18. IFN1 Enhances Thrombocyte Phagocytosis through IFN Receptor Complex-JAK/STAT-Complement C3.3-CR1 Pathway and Facilitates Antibacterial Immune Regulation in Teleost.
Zhu W; Zhang Y; Liao Z; Huo X; Yang C; Zhang Y; Su J
J Immunol; 2023 Apr; 210(8):1043-1058. PubMed ID: 36883974
[TBL] [Abstract][Full Text] [Related]
19. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.
Tannir NM; Cohen L; Wang X; Thall P; Mathew PF; Jonasch E; Siefker-Radtke A; Pagliaro LC; Ng CS; Logothetis C
Cancer; 2006 Nov; 107(9):2254-61. PubMed ID: 17029276
[TBL] [Abstract][Full Text] [Related]
20. Superior Antitumor Efficacy of IFN-α2b-Incorporated Photo-Cross-Linked Hydrogels Combined with T Cell Transfer and Low-Dose Irradiation Against Gastric Cancer.
Liu Q; Zhang D; Qian H; Chu Y; Yang Y; Shao J; Xu Q; Liu B
Int J Nanomedicine; 2020; 15():3669-3680. PubMed ID: 32547021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
